ALMSNasdaqPharmaceutical PreparationsFiscal year ends December 31
ALUMIS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$6.34+0.22 (+3.59%)
Close on Oct 19, 2026
- Market cap
- $809.56M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
91.3%
118M of 129M shares
Institutional holders
198
30 new, 24 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
40 buys · 9 sales
Net bought $60.13M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Deep Track Capital, LP | 7,362,035 | 5.98% | 13G (passive) | Mar 30, 2026 |
| BlackRock, Inc. | 7,069,502 | 5.70% | 13G (passive) | Jun 30, 2026 |
| Abigail P. Johnson | 6,769,170 | 5.50% | 13G (passive) | Jun 30, 2026 |
| Srinivas Akkaraju | 6,345,219 | 5.40% | 13D (active) amendment | Jan 9, 2026 |
| Samsara BioCapital, L.P. | 4,801,370 | 5.00% | 13D (active) amendment | May 21, 2025 |
| James B. Tananbaum | 15,693,820 | 12.70% | 13D (active) amendment | Apr 1, 2026 |
| David E. Goel | 15,139,707 | 15.80% | 13D (active) amendment | May 21, 2025 |
| AyurMaya Capital Management Company, LP | 15,139,707 | 12.30% | 13D (active) amendment | May 14, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ALMS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| AyurMaya Capital Management Company, LP | 15,139,707 | 11.70% | $426.03M | – | 100.00% |
| BlackRock, Inc. | 8,218,151 | 6.35% | $231.26M | +1,047,283 | 0.00% |
| FMR LLC | 6,769,170 | 5.23% | $190.48M | +5,795,388 | 0.01% |
| Deep Track Capital, LP | 6,348,558 | 4.90% | $178.65M | −424,037 | 2.60% |
| Samsara BioCapital, LLC | 6,345,219 | 4.90% | $178.55M | – | 14.67% |
| Foresite Capital Management V, LLC | 5,896,995 | 4.56% | $165.94M | – | 45.81% |
| Price T Rowe Associates Inc /Md/ | 5,199,838 | 4.02% | $146.33K | +1,913,085 | 0.01% |
| venBio Partners LLC | 4,528,408 | 3.50% | $127.43M | – | 24.53% |
| Foresite Capital Management VI LLC | 4,247,670 | 3.28% | $119.53M | – | 18.60% |
| Vanguard Capital Management LLC | 4,215,703 | 3.26% | $118.63M | +183,437 | 0.00% |
| Nextech Invest, Ltd. | 3,540,998 | 2.74% | $99.64M | – | 4.73% |
| Cormorant Asset Management, LP | 3,285,596 | 2.54% | $92.46M | −663,645 | 4.74% |
| Saturn V Capital Management LP | 2,915,443 | 2.25% | $82.04M | −286,632 | 11.76% |
| Octagon Capital Advisors LP | 2,830,700 | 2.19% | $79.66M | – | 7.16% |
| Jupiter Topco LLC | 2,355,122 | 1.82% | $66.24M | New | 0.03% |
| State Street Corp | 2,187,266 | 1.69% | $61.55M | +385,454 | 0.00% |
| Geode Capital Management, LLC | 2,168,517 | 1.68% | $61.03M | +250,102 | 0.00% |
| Mpm Bioimpact LLC | 2,019,020 | 1.56% | $56.82M | −367,509 | 3.46% |
| Baker Bros. Advisors LP | 2,012,500 | 1.55% | $56.63M | – | 0.28% |
| Sr One Capital Management, LP | 1,959,896 | 1.51% | $55.15M | – | 5.31% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 198 | 118M | 91.3% | 30 / 74 | 61 / 24 | 17M | 11M |
| Q1 2026 | 196 | 115M | 88.7% | 89 / 61 | 33 / 24 | 44M | 5M |
| Q4 2025 | 134 | 79M | 61.1% | 30 / 47 | 34 / 25 | 15M | 13M |
| Q3 2025 | 130 | 78M | 60.5% | 33 / 38 | 30 / 15 | 6M | 6M |
| Q2 2025 | 112 | 78M | 60.5% | 53 / 49 | 2 / 13 | 38M | 0M |
| Q1 2025 | 72 | 40M | 31.1% | 20 / 29 | 5 / 10 | 3M | 1M |
| Q4 2024 | 64 | 40M | 31.1% | 15 / 24 | 7 / 3 | 5M | 0M |
| Q3 2024 | 52 | 35M | 27.2% | 35 / 5 | 5 / 12 | 8M | 1M |
| Q2 2024 | 29 | 29M | 22.1% | 29 / 0 | 0 / 0 | 29M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ALMS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,139,756 | 2.43% | $88.35M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,020,285 | 1.56% | $56.85M | 0.07% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,369,916 | 1.06% | $38.55M | 0.26% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 1,103,470 | 0.85% | $31.17M | 0.35% | Jul 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 1,103,000 | 0.85% | $31.16M | 0.42% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,088,300 | 0.84% | $30.62M | 0.31% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 977,098 | 0.75% | $27.50M | 0.03% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 946,500 | 0.73% | $26.74M | 1.22% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 863,916 | 0.67% | $24.41M | 0.07% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 682,035 | 0.53% | $19.19M | 0.12% | Jun 30, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 633,300 | 0.49% | $17.89M | 0.38% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 620,000 | 0.48% | $13.39M | 0.25% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 594,923 | 0.46% | $16.74M | 0.14% | Jun 30, 2026 |
| iShares Biotechnology ETF | 594,125 | 0.46% | $16.72M | 0.18% | Jun 30, 2026 |
| Fidelity Small Cap Growth K6 Fund | 572,460 | 0.44% | $16.17M | 0.35% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Martin Babler | President, CEO and Chairman, Director | 109,454 | 0.08% | Jan 28, 2026 |
| Sanam Pangali | Chief Legal Officer | 9,747 | 0.01% | Aug 5, 2026 |
| Mark Christopher Bradley | Chief Development Officer | 68,559 | 0.05% | Aug 5, 2026 |
| John R. Schroer | Chief Financial Officer | 24,718 | 0.02% | Aug 5, 2026 |
| Roy C. Hardiman | Chief Business & Strategy Ofcr | 214,163 | 0.17% | Aug 5, 2026 |
| David M. Goldstein | Chief Scientific Officer | 248,201 | 0.19% | Aug 5, 2026 |
| Jorn Drappa | Chief Medical Officer | 56,892 | 0.04% | Aug 5, 2026 |
| Derrick Richardson | SVP, People and Culture | 42,800 | 0.03% | Jul 31, 2025 |
| Sara Klein | Chief Legal Officer | 33,796 | 0.03% | Feb 20, 2025 |
| Srinivas Akkaraju | Director | 6,966,072 | 5.38% | Sep 9, 2026 |
| Patrick Machado | Director | 10,617 | 0.01% | Jul 2, 2026 |
| Lynn A. Tetrault | Director | 3,553 | 0.00% | Jul 2, 2026 |
| Sapna Srivastava | Director | 3,553 | 0.00% | Jul 2, 2026 |
| Zhengbin Yao | Director | 27,082 | 0.02% | Jul 2, 2026 |
| James B. Tananbaum | Director, 10% owner | 1,123,337 | 0.87% | Apr 3, 2026 |
| David E. Goel | Director, 10% owner | 10,645,966 | 8.22% | May 23, 2025 |
| AyurMaya Capital Management Company, LP | Director, 10% owner | 15,139,707 | 11.70% | May 23, 2025 |
| Alan Colowick | Director | 18,404 | 0.01% | Apr 3, 2025 |
| Foresite Capital Fund V, L.P. | 10% owner | – | – | Apr 3, 2026 |
| Foresite Capital Opportunity Fund V, L.P. | 10% owner | – | – | Apr 3, 2026 |
| Foresite Capital Opportunity Management V, LLC | 10% owner | 3,067,571 | 2.37% | Apr 3, 2026 |
| Foresite Labs Affiliates 2021, LLC | 10% owner | 0 | – | Apr 3, 2026 |
| Foresite Labs Fund I, L.P. | 10% owner | 2,908,332 | 2.25% | Apr 3, 2026 |
| Foresite Labs Management I, LLC | 10% owner | 4,247,670 | 3.28% | Apr 3, 2026 |
| Labs Co-Invest V, LLC | 10% owner | – | – | Apr 3, 2026 |
| Capital Fund VI LP Foresite | 10% owner | – | – | Apr 3, 2026 |
| Foresite Labs, LLC | 10% owner | 2,908,332 | 2.25% | Apr 3, 2026 |
| Foresite Capital Management V, LLC | 10% owner | – | – | Apr 3, 2026 |
| Capital Management VI LLC Foresite | 10% owner | 1,123,337 | 0.87% | Apr 3, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Srinivas Akkaraju Director | Sep 8, 2026 | Sale | −48,065 | $10.55 | $507.09K | 2,025,493 |
| Srinivas Akkaraju Director | Sep 8, 2026 | Buy | +273,290 | $10.63 | $2.91M | 2,298,783 |
| Srinivas Akkaraju Director | Sep 8, 2026 | Buy | +273,291 | $10.63 | $2.91M | 4,937,026 |
| Srinivas Akkaraju Director | Sep 8, 2026 | Sale | −48,066 | $10.55 | $507.10K | 4,663,735 |
| Srinivas Akkaraju Director | Sep 4, 2026 | Buy | +220,070 | $11.17 | $2.46M | 4,711,801 |
| Srinivas Akkaraju Director | Sep 4, 2026 | Buy | +220,070 | $11.17 | $2.46M | 2,073,558 |
| Roy C. Hardiman Chief Business & Strategy Ofcr | Aug 3, 2026 | Sale | −2,692 | $26.37 | $70.99K | 207,746 |
| David M. Goldstein Chief Scientific Officer | Aug 3, 2026 | Sale | −2,596 | $26.37 | $68.46K | 30,970 |
| Jorn Drappa Chief Medical Officer | Aug 3, 2026 | Sale | −2,447 | $26.37 | $64.53K | 56,892 |
| Mark Christopher Bradley Chief Development Officer | Aug 3, 2026 | Sale | −2,572 | $26.37 | $67.82K | 48,533 |
| Sanam Pangali Chief Legal Officer | Aug 3, 2026 | Sale | −1,364 | $26.37 | $35.97K | 9,747 |
| John R. Schroer Chief Financial Officer | Aug 3, 2026 | Sale | −3,282 | $26.37 | $86.55K | 24,718 |
| Sanam Pangali Chief Legal Officer | Jul 6, 2026 | Sale | −5,000 | $28.00 | $140.00K | 11,111 |
| Sanam Pangali Chief Legal Officer | Jul 6, 2026 | Option exercise | +5,000 | $5.06 | $25.30K | 16,111 |
| Zhengbin Yao Director | Jun 30, 2026 | Award | +3,553 | – | – | 27,082 |
| Srinivas Akkaraju Director | Jun 30, 2026 | Award | +3,553 | – | – | 3,553 |
| Sapna Srivastava Director | Jun 30, 2026 | Award | +3,553 | – | – | 3,553 |
| Lynn A. Tetrault Director | Jun 30, 2026 | Award | +3,553 | – | – | 3,553 |
| Patrick Machado Director | Jun 30, 2026 | Award | +3,553 | – | – | 3,553 |
| Jorn Drappa Chief Medical Officer | May 22, 2026 | Option exercise | +11,317 | $8.84 | $100.04K | 43,804 |
| Jorn Drappa Chief Medical Officer | May 22, 2026 | Option exercise | +15,535 | $5.06 | $78.61K | 59,339 |
| Foresite Labs Affiliates 2021, LLC 10% owner | Apr 1, 2026 | Other | −1,123,337 | – | – | 0 |
| Foresite Labs Affiliates 2021, LLC 10% owner | Apr 1, 2026 | Other | −1,176,470 | – | – | 0 |
| Foresite Labs Affiliates 2021, LLC 10% owner | Apr 1, 2026 | Other | +680,486 | – | – | 680,486 |
| Foresite Labs Affiliates 2021, LLC 10% owner | Apr 1, 2026 | Other | +1,123,337 | – | – | 1,123,337 |
| Capital Management VI LLC Foresite 10% owner | Apr 1, 2026 | Other | +1,123,337 | – | – | 1,123,337 |
| Capital Management VI LLC Foresite 10% owner | Apr 1, 2026 | Other | +680,486 | – | – | 680,486 |
| Capital Management VI LLC Foresite 10% owner | Apr 1, 2026 | Other | −1,123,337 | – | – | 0 |
| Capital Management VI LLC Foresite 10% owner | Apr 1, 2026 | Other | −1,176,470 | – | – | 0 |
| James B. Tananbaum Director, 10% owner | Apr 1, 2026 | Other | +1,123,337 | – | – | 1,123,337 |
| James B. Tananbaum Director, 10% owner | Apr 1, 2026 | Other | −1,176,470 | – | – | 0 |
| James B. Tananbaum Director, 10% owner | Apr 1, 2026 | Other | −1,123,337 | – | – | 0 |
| James B. Tananbaum Director, 10% owner | Apr 1, 2026 | Other | +680,486 | – | – | 680,486 |
| Srinivas Akkaraju Director | Jan 9, 2026 | Buy | +588,235 | $17.00 | $10.00M | 1,853,488 |
| Foresite Labs, LLC 10% owner | Jan 8, 2026 | Buy | +294,117 | $17.00 | $5.00M | 2,908,332 |
| Foresite Labs, LLC 10% owner | Jan 8, 2026 | Buy | +117,647 | $17.00 | $2.00M | 5,702,536 |
| James B. Tananbaum Director, 10% owner | Jan 8, 2026 | Buy | +117,647 | $17.00 | $2.00M | 5,702,536 |
| James B. Tananbaum Director, 10% owner | Jan 8, 2026 | Buy | +294,117 | $17.00 | $5.00M | 2,908,332 |
| Foresite Labs Fund I, L.P. 10% owner | Jan 8, 2026 | Buy | +294,117 | $17.00 | $5.00M | 2,908,332 |
| Foresite Labs Fund I, L.P. 10% owner | Jan 8, 2026 | Buy | +117,647 | $17.00 | $2.00M | 5,702,536 |
| Srinivas Akkaraju Director | Dec 5, 2025 | Buy | +64,969 | $8.95 | $581.47K | 1,143,845 |
| Srinivas Akkaraju Director | Dec 5, 2025 | Buy | +51,380 | $10.73 | $551.31K | 1,265,253 |
| Srinivas Akkaraju Director | Dec 5, 2025 | Buy | +70,028 | $10.01 | $700.98K | 1,213,873 |
| Srinivas Akkaraju Director | Dec 4, 2025 | Buy | +66,027 | $8.18 | $540.10K | 1,078,876 |
| Srinivas Akkaraju Director | Dec 3, 2025 | Buy | +100,000 | $7.75 | $775.00K | 1,012,849 |
| Srinivas Akkaraju Director | Dec 2, 2025 | Buy | +96,000 | $7.55 | $724.80K | 912,849 |
| Srinivas Akkaraju Director | Dec 1, 2025 | Buy | +86,350 | $7.46 | $644.17K | 816,849 |
| Srinivas Akkaraju Director | Nov 28, 2025 | Buy | +38,702 | $7.64 | $295.68K | 730,499 |
| Srinivas Akkaraju Director | Nov 26, 2025 | Buy | +48,537 | $7.64 | $370.82K | 691,797 |
| Foresite Labs Fund I, L.P. 10% owner | Nov 21, 2025 | Buy | +72,212 | $7.38 | $532.92K | 2,614,215 |
| Foresite Labs Affiliates 2021, LLC 10% owner | Nov 21, 2025 | Buy | +72,212 | $7.38 | $532.92K | 2,614,215 |
| James B. Tananbaum Director, 10% owner | Nov 21, 2025 | Buy | +72,212 | $7.38 | $532.92K | 2,614,215 |
| Srinivas Akkaraju Director | Nov 20, 2025 | Buy | +125,743 | $7.20 | $905.35K | 643,260 |
| Foresite Labs Affiliates 2021, LLC 10% owner | Nov 19, 2025 | Buy | +190,500 | $6.56 | $1.25M | 2,542,003 |
| Srinivas Akkaraju Director | Nov 19, 2025 | Buy | +137,772 | $6.56 | $903.78K | 517,517 |
| James B. Tananbaum Director, 10% owner | Nov 19, 2025 | Buy | +190,500 | $6.56 | $1.25M | 2,542,003 |
| Capital Management VI LLC Foresite 10% owner | Nov 19, 2025 | Buy | +190,500 | $6.56 | $1.25M | 2,542,003 |
| Foresite Labs Affiliates 2021, LLC 10% owner | Nov 18, 2025 | Buy | +117,374 | $6.19 | $726.55K | 2,351,503 |
| Srinivas Akkaraju Director | Nov 18, 2025 | Buy | +102,652 | $6.05 | $621.04K | 379,745 |
| James B. Tananbaum Director, 10% owner | Nov 18, 2025 | Buy | +117,374 | $6.19 | $726.55K | 2,351,503 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Pangali Sanampreet Officer | Jul 6, 2026 | 5,000 | $140.00K | Jul 6, 2026 | Stock Option Exercise |